Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Skye Bioscience announces special virtual investor presentation » 09:01
09/14/21
09/14
09:01
09/14/21
09:01
SKYE

Skye Bioscience

/

+

Skye Bioscience announced…

Skye Bioscience announced that it will host a special virtual investor presentation on Tuesday, October 12. The filmed broadcast of this virtual event will be available beginning at 1 p.m. ET/10:00 a.m. PT. The agenda will include the company's strategic direction and business outlook for 2022, clinical development updates on the company's lead glaucoma program, R&D advancements and new initiatives, followed by Q&A. Speakers for this event will include Skye's executive management team in addition to select members of its scientific and clinical advisory boards.

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

Over a month ago
Hot Stocks
Skye Bioscience completes THCVHS IND-enabling in vitro genotoxicity studies » 08:54
08/10/21
08/10
08:54
08/10/21
08:54
SKYE

Skye Bioscience

/

+

Skye Bioscience has…

Skye Bioscience has successfully completed genotoxicity studies of THCVHS required prior to beginning its planned Phase 1 clinical study in Australia. Skye is initially developing THCVHS as a treatment of glaucoma. Genotoxicity safety studies are required by both the Australian Therapeutic Goods Administration and the U.S. Food & Drug Administration prior to initiating human trials and were completed at BioReliance Corporation under Good Laboratory Practices regulations, which meet the standards for both agencies. Two studies were carried out to assess the genotoxicity potential of THCVHS. The first was a mammalian cell micronucleus assay, which is designed to determine a compound's ability to generate chromosomal aberrations and considered to be one of the most reliable assays in determining genotoxicity. The second study was a reverse bacterial mutagenesis assay, also referred to as the Ames test, which assesses the ability of a compound to generate gene mutations. Both assays produced negative results indicating that THCVHS is not a genotoxic compound, clearing a key step to allow for human trials.

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

Conference/Events
OTC Markets Group to hold a virtual conference » 10:12
08/05/21
08/05
10:12
08/05/21
10:12
SKYE

Skye Bioscience

/

+

OTCQB Venture Virtual…

OTCQB Venture Virtual Investor Conference will be held on August 5. Webcast Link

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

Syndicate
Skye Bioscience files $75M mixed securities shelf  06:47
07/29/21
07/29
06:47
07/29/21
06:47
SKYE

Skye Bioscience

/

+

 
ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

Hot Stocks
Skye Bioscience appoints Praveen Tyle to board of directors » 08:36
07/26/21
07/26
08:36
07/26/21
08:36
SKYE

Skye Bioscience

/

+

Skye Bioscience has…

Skye Bioscience has appointed Praveen Tyle, Ph.D., as an independent director to the Company's board. Tyle is currently President & CEO and a director of Invectys, Inc, an immuno-oncology company spun out of the world-renowned Pasteur Institute.

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

SKYE Skye Bioscience
/

+

Over a quarter ago
Hot Stocks
Skye Bioscience adds Miguel Gonzalez-Andrades to clinical advisory board » 08:40
06/10/21
06/10
08:40
06/10/21
08:40
SKYE

Skye Bioscience

/

+

Skye Bioscience has…

Skye Bioscience has expanded its Clinical Advisory Board with the appointment of ophthalmology expert and innovator, Miguel Gonzalez-Andrades, MD, PhD. Miguel Gonzalez-Andrades is a clinician-scientist currently working as an ophthalmologist in the Ophthalmology Unit at Reina Sofia University Hospital, and as assistant professor and research scientist at Maimonides Biomedical Research Institute of Cordoba-University of Cordoba. Additionally, he serves since 2019 as an adjunct scientist at the Schepens Eye Research Institute and Mass Eye and Ear, Harvard Medical School. Currently, he is the Chair of the Young Section of the European Society of Ophthalmology.

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

SKYE Skye Bioscience
/

+

Hot Stocks
Skye Bioscience announces results from preclinical study on THCVHS » 08:46
05/17/21
05/17
08:46
05/17/21
08:46
SKYE

Skye Bioscience

/

+

Skye Bioscience announced…

Skye Bioscience announced that in a preclinical study assessing intraocular pressure, or IOP,-lowering effects of its novel prodrug, THCVHS combined with netarsudil demonstrated the most significant IOP-lowering effects and duration of activity compared to all other tested single and combined treatments. Data from this study also highlighted THCVHS' superior IOP-lowering capability and duration of activity as a single agent compared to the current standard of care for the treatment of glaucoma, latanoprost. This study demonstrated that THCVHS combined with netarsudil achieved superior IOP-lowering and durability compared to latanoprost. Latanoprost's average maximum IOP-lowering effect was 21.3% and it returned to baseline after 9 hours; THCVHS combined with netarsudil achieved an average maximum IOP-lowering effect of 32.4% and retained an average reduction in IPO of 26.5% at 9 hours. The data also showed superior IOP-lowering compared to netarsudil combined with latanoprost. This study also reaffirmed THCVHS' superior ability to significantly lower IOP over a longer duration compared to latanoprost: THCVHS achieved an average maximum reduction in IOP of 27.5% and maintained an average reduction in IOP of 21.1% after 9 hours, at which point latanoprost had returned to baseline.

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

SKYE Skye Bioscience
/

+

Hot Stocks
Skye Bioscience completes CMC, GLP production for THCVHS lead program » 08:43
04/22/21
04/22
08:43
04/22/21
08:43
SKYE

Skye Bioscience

/

+

Skye Bioscience has…

Skye Bioscience has established its Chemical, Manufacture and Controls procedures for the production of THCVHS drug product suitable for Good Laboratory Practice non-clinical research. This is a key step in advancing the Company's planned Phase 1 study for its lead drug candidate, THCVHS, a novel prodrug of THC for the treatment of glaucoma. Additional Updates on the THCVHS Program: Preclinical pharmacology studies of THCVHS in rabbits has been completed. These studies compared THCVHS' effect on intraocular pressure versus netarsudil and latanoprost and evaluated the potential additive and synergistic effects of THCVHS with these agents. A manuscript is being drafted to summarize this data and the company looks forward to reporting results before the end of the quarter. Regulatory requirements for the neuroprotection study being conducted by the CRO, Experimentica UAB, have been received. The company is in the process of shipping drug material, which will allow for the CRO to initiate the study imminently. A genotoxicity study underway will validate that THCVHS has no effect on the genetic material of cells that may lead to mutations that could cause cancer. This is another data set required by the Australian TGA, as well as the US FDA, before receiving regulatory clearance to conduct human clinical trials. The company plans to initiate its first-in-human Phase 1 study of THCVHS for the treatment of glaucoma before the end of the year.

ShowHide Related Items >><<
SKYE Skye Bioscience
/

+

SKYE Skye Bioscience
/

+

Conference/Events
SNN Network to hold a virtual event » 04:55
04/22/21
04/22
04:55
04/22/21
04:55
VMAR

Vision Marine Technologies

$6.60 /

+0.51 (+8.37%)

, GROW

U.S. Global Investors

$7.59 /

+0.33 (+4.55%)

, PYR

PyroGenesis

$5.20 /

+0.3 (+6.12%)

, SKYE

Skye Bioscience

/

+

, MEDS

Trxade Health

$4.48 /

+0.22 (+5.16%)

, ENVB

Enveric Biosciences

$2.32 /

+0.155 (+7.18%)

, SOLO

ElectraMeccanica

$4.23 /

+0.285 (+7.22%)

, DUOT

Duos Technologies Group

$8.50 /

+0.51 (+6.38%)

, CTHR

Charles & Colvard

$2.90 /

+0.11 (+3.94%)

, BMM

Bimini Mortgage Management

/

+

, ARHH

Assure Holdings

$1.23 /

-0.00851 (-0.69%)

, HSDT

Helius Medical

$17.91 /

+0.815 (+4.77%)

, ISDR

Issuer Direct

$24.97 /

+0.45 (+1.84%)

Planet MicroCap Virtual…

Planet MicroCap Virtual Showcase will be held on April 20-22. Webcast Link

ShowHide Related Items >><<
VMAR Vision Marine Technologies
$6.60 /

+0.51 (+8.37%)

SOLO ElectraMeccanica
$4.23 /

+0.285 (+7.22%)

SKYE Skye Bioscience
/

+

PYR PyroGenesis
$5.20 /

+0.3 (+6.12%)

MEDS Trxade Health
$4.48 /

+0.22 (+5.16%)

HSDT Helius Medical
$17.91 /

+0.815 (+4.77%)

GROW U.S. Global Investors
$7.59 /

+0.33 (+4.55%)

ENVB Enveric Biosciences
$2.32 /

+0.155 (+7.18%)

CTHR Charles & Colvard
$2.90 /

+0.11 (+3.94%)

ARHH Assure Holdings
$1.23 /

-0.00851 (-0.69%)

VMAR Vision Marine Technologies
$6.60 /

+0.51 (+8.37%)

01/11/21 ThinkEquity
Vision Marine Technologies initiated with a Buy at ThinkEquity
GROW U.S. Global Investors
$7.59 /

+0.33 (+4.55%)

PYR PyroGenesis
$5.20 /

+0.3 (+6.12%)

SKYE Skye Bioscience
/

+

MEDS Trxade Health
$4.48 /

+0.22 (+5.16%)

02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Maxim
Trxade Group initiated with a Buy at Maxim
12/03/20 National Securities
Trxade Group initiated with a Buy at National Securities
ENVB Enveric Biosciences
$2.32 /

+0.155 (+7.18%)

SOLO ElectraMeccanica
$4.23 /

+0.285 (+7.22%)

12/16/20 Stifel
ElectraMeccanica initiated with a Buy at Stifel
12/16/20 Colliers
ElectraMeccanica initiated with a Buy at Colliers
11/23/20 Roth Capital
ElectraMeccanica price target raised to $12.25 from $7.50 at Roth Capital
10/29/20 Roth Capital
Roth reiterates Buy rating on ElectraMeccanica after first deliveries from China
DUOT Duos Technologies Group
$8.50 /

+0.51 (+6.38%)

CTHR Charles & Colvard
$2.90 /

+0.11 (+3.94%)

BMM Bimini Mortgage Management
/

+

ARHH Assure Holdings
$1.23 /

-0.00851 (-0.69%)

HSDT Helius Medical
$17.91 /

+0.815 (+4.77%)

03/24/21
Fly Intel: Top five analyst initiations
03/24/21 Noble Capital
Helius Medical initiated with an Outperform at Noble Capital
02/12/21 Ladenburg
Helius Medical initiated with a Buy at Ladenburg
ISDR Issuer Direct
$24.97 /

+0.45 (+1.84%)

08/25/20 Northland
Issuer Direct price target raised to $18 from $16 at Northland
SOLO ElectraMeccanica
$4.23 /

+0.285 (+7.22%)

MEDS Trxade Health
$4.48 /

+0.22 (+5.16%)

CTHR Charles & Colvard
$2.90 /

+0.11 (+3.94%)

ARHH Assure Holdings
$1.23 /

-0.00851 (-0.69%)

  • 28
    Jan
  • 24
    Nov
SOLO ElectraMeccanica
$4.23 /

+0.285 (+7.22%)

HSDT Helius Medical
$17.91 /

+0.815 (+4.77%)

VMAR Vision Marine Technologies
$6.60 /

+0.51 (+8.37%)

SKYE Skye Bioscience
/

+

MEDS Trxade Health
$4.48 /

+0.22 (+5.16%)

HSDT Helius Medical
$17.91 /

+0.815 (+4.77%)

ENVB Enveric Biosciences
$2.32 /

+0.155 (+7.18%)

SOLO ElectraMeccanica
$4.23 /

+0.285 (+7.22%)

Conference/Events
SNN Network to hold a virtual event » 04:55
04/21/21
04/21
04:55
04/21/21
04:55
VMAR

Vision Marine Technologies

$6.09 /

-0.095 (-1.54%)

, GROW

U.S. Global Investors

$7.26 /

-0.38 (-4.97%)

, PYR

PyroGenesis

$4.90 /

-0.02 (-0.41%)

, SKYE

Skye Bioscience

/

+

, MEDS

Trxade Health

$4.26 /

-0.05 (-1.16%)

, ENVB

Enveric Biosciences

$2.16 /

-0.12 (-5.26%)

, SOLO

ElectraMeccanica

$3.95 /

-0.115 (-2.83%)

, DUOT

Duos Technologies Group

$7.99 /

-0.01 (-0.13%)

, CTHR

Charles & Colvard

$2.79 /

-0.16 (-5.42%)

, BMM

Bimini Mortgage Management

/

+

, ARHH

Assure Holdings

$1.24 /

-0.00099 (-0.08%)

, HSDT

Helius Medical

$17.09 /

-0.225 (-1.30%)

, ISDR

Issuer Direct

$24.52 /

+0.6 (+2.51%)

Planet MicroCap Virtual…

Planet MicroCap Virtual Showcase will be held on April 20-22. Webcast Link

ShowHide Related Items >><<
VMAR Vision Marine Technologies
$6.09 /

-0.095 (-1.54%)

SOLO ElectraMeccanica
$3.95 /

-0.115 (-2.83%)

SKYE Skye Bioscience
/

+

PYR PyroGenesis
$4.90 /

-0.02 (-0.41%)

MEDS Trxade Health
$4.26 /

-0.05 (-1.16%)

HSDT Helius Medical
$17.09 /

-0.225 (-1.30%)

GROW U.S. Global Investors
$7.26 /

-0.38 (-4.97%)

ENVB Enveric Biosciences
$2.16 /

-0.12 (-5.26%)

CTHR Charles & Colvard
$2.79 /

-0.16 (-5.42%)

ARHH Assure Holdings
$1.24 /

-0.00099 (-0.08%)

VMAR Vision Marine Technologies
$6.09 /

-0.095 (-1.54%)

01/11/21 ThinkEquity
Vision Marine Technologies initiated with a Buy at ThinkEquity
GROW U.S. Global Investors
$7.26 /

-0.38 (-4.97%)

PYR PyroGenesis
$4.90 /

-0.02 (-0.41%)

SKYE Skye Bioscience
/

+

MEDS Trxade Health
$4.26 /

-0.05 (-1.16%)

02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Maxim
Trxade Group initiated with a Buy at Maxim
12/03/20 National Securities
Trxade Group initiated with a Buy at National Securities
ENVB Enveric Biosciences
$2.16 /

-0.12 (-5.26%)

SOLO ElectraMeccanica
$3.95 /

-0.115 (-2.83%)

12/16/20 Stifel
ElectraMeccanica initiated with a Buy at Stifel
12/16/20 Colliers
ElectraMeccanica initiated with a Buy at Colliers
11/23/20 Roth Capital
ElectraMeccanica price target raised to $12.25 from $7.50 at Roth Capital
10/29/20 Roth Capital
Roth reiterates Buy rating on ElectraMeccanica after first deliveries from China
DUOT Duos Technologies Group
$7.99 /

-0.01 (-0.13%)

CTHR Charles & Colvard
$2.79 /

-0.16 (-5.42%)

BMM Bimini Mortgage Management
/

+

ARHH Assure Holdings
$1.24 /

-0.00099 (-0.08%)

HSDT Helius Medical
$17.09 /

-0.225 (-1.30%)

03/24/21
Fly Intel: Top five analyst initiations
03/24/21 Noble Capital
Helius Medical initiated with an Outperform at Noble Capital
02/12/21 Ladenburg
Helius Medical initiated with a Buy at Ladenburg
ISDR Issuer Direct
$24.52 /

+0.6 (+2.51%)

08/25/20 Northland
Issuer Direct price target raised to $18 from $16 at Northland
SOLO ElectraMeccanica
$3.95 /

-0.115 (-2.83%)

MEDS Trxade Health
$4.26 /

-0.05 (-1.16%)

CTHR Charles & Colvard
$2.79 /

-0.16 (-5.42%)

ARHH Assure Holdings
$1.24 /

-0.00099 (-0.08%)

  • 28
    Jan
  • 24
    Nov
SOLO ElectraMeccanica
$3.95 /

-0.115 (-2.83%)

HSDT Helius Medical
$17.09 /

-0.225 (-1.30%)

VMAR Vision Marine Technologies
$6.09 /

-0.095 (-1.54%)

SKYE Skye Bioscience
/

+

MEDS Trxade Health
$4.26 /

-0.05 (-1.16%)

HSDT Helius Medical
$17.09 /

-0.225 (-1.30%)

ENVB Enveric Biosciences
$2.16 /

-0.12 (-5.26%)

SOLO ElectraMeccanica
$3.95 /

-0.115 (-2.83%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.